Related references
Note: Only part of the references are listed.Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial
G. A. Amos Burke et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
Fabian Knoerr et al.
HAEMATOLOGICA (2021)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Nancy L. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring
Nadine Wenningmann et al.
MOLECULAR PHARMACOLOGY (2019)
A prospective study of mediastinal gray-zone lymphoma
Wyndham H. Wilson et al.
BLOOD (2014)
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Kieron Dunleavy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
Mary Gerrard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH
M Gutierrez et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
